Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 12/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1044308 | 0.86 | S1PR3 (0.41) | S1PR3S1PR1HSD11B1GAAPIM1 | |
| SCHEMBL1076624 | 0.84 | S1PR3 (0.43) | S1PR3S1PR1HSD11B1GAATSHR | |
| SCHEMBL1041774 | 0.84 | S1PR3 (0.40) | S1PR3S1PR1HSD11B1GAAPIM1 | |
| SCHEMBL1045040 | 0.84 | S1PR3 (0.40) | S1PR3S1PR1HSD11B1GAATSHR | |
| SCHEMBL15122035 | 0.83 | ALDH1A1 (0.35) | S1PR3HSD11B1GAAALDH1A1KMT2A | |
| SCHEMBL1044674 | 0.83 | S1PR3 (0.41) | S1PR3S1PR1HSD11B1GAATSHR | |
| SCHEMBL1043939 | 0.82 | S1PR3 (0.40) | S1PR3S1PR1HSD11B1GAATSHR | |
| SCHEMBL1045030 | 0.82 | S1PR3 (0.42) | S1PR3S1PR1HSD11B1GAATSHR | |
| SCHEMBL3454477 | 0.82 | S1PR3 (0.43) | S1PR3S1PR1HSD11B1GAAPIM1 | |
| SCHEMBL1041977 | 0.82 | S1PR3 (0.42) | S1PR3S1PR1HSD11B1GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546575-B2 | NIP thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydroge-nase-1 | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | claimed |
| EP-2271405-B1 | NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2013-07-24 | — | — | EP | claimed |
| US-20110060007-A1 | Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1 | Merck Patent Gesellschaft Mit Beschrankter Haftling (DE) | 2011-03-10 | — | — | US | claimed |
| EP-2271405-A2 | NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDORXYSTEROID DEHYDROGENASE-1 | Merck Patent GmbH (DE) | 2011-01-12 | — | — | EP | claimed |
| WO-2009135581-A9 | NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2010-11-11 | — | — | WO | claimed |
| WO-2009135581-A2 | NOVEL NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2009-11-12 | — | — | WO | claimed |
| US-8546575-B2 | NIP thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydroge-nase-1 | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| EP-2271405-B1 | NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2013-07-24 | — | — | EP | disclosed |
| US-20110060007-A1 | Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1 | Merck Patent Gesellschaft Mit Beschrankter Haftling (DE) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060007-A1 | Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1 | HSD11B1, HSD17B1, HSD11B2 | S1PR3 4823/4885S1PR1 4265/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.